scPharmaceuticals Inc. (SCPH)
- Previous Close
4.3500 - Open
4.3800 - Bid 4.4800 x 100
- Ask 4.5200 x 100
- Day's Range
4.3300 - 4.5800 - 52 Week Range
4.2500 - 12.7500 - Volume
111,838 - Avg. Volume
221,501 - Market Cap (intraday)
161.884M - Beta (5Y Monthly) 0.05
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4200 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.50
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
www.scpharmaceuticals.comRecent News: SCPH
Performance Overview: SCPH
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SCPH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SCPH
Valuation Measures
Market Cap
161.88M
Enterprise Value
126.14M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.72
Price/Book (mrq)
4.35
Enterprise Value/Revenue
9.28
Enterprise Value/EBITDA
-2.74
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-31.67%
Return on Equity (ttm)
-99.97%
Revenue (ttm)
13.59M
Net Income Avi to Common (ttm)
-54.81M
Diluted EPS (ttm)
-1.4200
Balance Sheet and Cash Flow
Total Cash (mrq)
76.99M
Total Debt/Equity (mrq)
108.20%
Levered Free Cash Flow (ttm)
-40.4M